Published in Ann Rheum Dis on October 17, 2008
Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin (2010) 1.63
Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am (2010) 1.41
Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum (2009) 1.36
Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. Ann Rheum Dis (2010) 1.26
Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol (2010) 1.23
Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther (2013) 1.07
Differences in disease phenotype and severity in SLE across age groups. Lupus (2016) 1.02
Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides. J Mol Med (Berl) (2010) 0.97
Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken) (2012) 0.97
Infections and systemic lupus erythematosus. Eur J Clin Microbiol Infect Dis (2014) 0.90
Clinical presentations and outcomes of Filipino juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J (2011) 0.84
Exercise training in childhood-onset systemic lupus erythematosus: a controlled randomized trial. Arthritis Res Ther (2013) 0.84
SLE: Another Autoimmune Disorder Influenced by Microbes and Diet? Front Immunol (2015) 0.81
Increased soluble phagocytic receptors sMer, sTyro3 and sAxl and reduced phagocytosis in juvenile-onset systemic lupus erythematosus. Pediatr Rheumatol Online J (2015) 0.80
Autoantibodies against C1q as a Diagnostic Measure of Lupus Nephritis: Systematic Review and Meta-analysis. J Clin Cell Immunol (2014) 0.80
Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo) (2012) 0.78
Juvenile and adult-onset systemic lupus erythematosus: an ethnicity-based comparison. Rheumatol Int (2010) 0.78
IFNα enhances the production of IL-6 by human neutrophils activated via TLR8. Sci Rep (2016) 0.77
Familial juvenile systemic lupus erythematosus in Arab children. Rheumatol Int (2011) 0.77
The pro-inflammatory potential of T cells in juvenile-onset systemic lupus erythematosus. Pediatr Rheumatol Online J (2014) 0.76
Scaly ear rash as the herald of a young girl with juvenile systemic lupus erythematosus. Ann Dermatol (2011) 0.75
Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus. Arthritis Res Ther (2011) 0.75
Gastrointestinal system manifestations in juvenile systemic lupus erythematosus. Clin Rheumatol (2017) 0.75
Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study. Clin Rheumatol (2017) 0.75
Differences in clinical features observed between childhood-onset versus adult-onset systemic lupus erythematosus: A systematic review and meta-analysis. Medicine (Baltimore) (2017) 0.75
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum (1996) 6.88
Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61
Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol (1999) 3.39
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum (2004) 3.38
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
Glycolipid antigen processing for presentation by CD1d molecules. Science (2001) 3.04
Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum (2001) 2.96
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood (1989) 2.78
Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis (2001) 2.69
Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum (2011) 2.53
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis (2010) 2.52
Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis (2004) 2.35
Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis (2005) 2.23
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis (2004) 2.18
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis (2004) 2.15
A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis (2004) 2.12
Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum (2007) 2.10
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis (2012) 2.06
Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor? Arthritis Rheum (2011) 2.01
The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol (1995) 1.99
An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum (2005) 1.96
Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.91
Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum (2002) 1.87
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis (2010) 1.79
Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2007) 1.78
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76
Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum (2009) 1.76
Long term high intensity exercise and damage of small joints in rheumatoid arthritis. Ann Rheum Dis (2004) 1.73
Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med (1988) 1.72
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum (2001) 1.70
Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun (2003) 1.70
Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) (1999) 1.66
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65
Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis Cartilage (2012) 1.62
A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis (2007) 1.61
Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.60
Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis (2002) 1.57
Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. Ann Rheum Dis (2012) 1.56
No increased risk of valvular heart disease in adult poststreptococcal reactive arthritis. Arthritis Rheum (2009) 1.53
Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum (2006) 1.51
The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol (1995) 1.51
Autologous matrix-induced chondrogenesis combined with platelet-rich plasma gel: technical description and a five pilot patients report. Knee Surg Sports Traumatol Arthrosc (2010) 1.51
Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis (2011) 1.50
Increased levels of antibodies to heat shock proteins with increasing age in Mrl/Mp-lpr/lpr mice. Br J Rheumatol (1995) 1.48
Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis (2000) 1.47
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis (2008) 1.46
Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum (1997) 1.46
Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun (1991) 1.45
Oral lyophylizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urol (2011) 1.45
The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol (1995) 1.44
Tuberculin skin test versus interferon-gamma release assays for the diagnosis of tuberculosis infection. Acta Clin Belg (2014) 1.43
Etiological factors and underlying conditions in patients with leucocytoclastic vasculitis. Clin Exp Rheumatol (1997) 1.42
An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford) (2006) 1.42
Autoimmune diseases--at the molecular level. Immunol Today (1993) 1.42
Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet (2000) 1.42
Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial. Arthritis Rheum (2009) 1.40
Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum (2009) 1.40
Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum (2000) 1.39
Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis (2011) 1.38
The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis (2007) 1.37
A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis (2005) 1.37
Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol (2000) 1.37
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus (2013) 1.36
Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol (1999) 1.36
A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J Autoimmun (1989) 1.36
Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J Rheumatol (1994) 1.35
Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol (1992) 1.34
Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis (2010) 1.34
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34
The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis (2007) 1.34
Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis (2004) 1.32
Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum (2008) 1.32
Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis (2005) 1.31
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis (2003) 1.31
Retracted Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad Sci U S A (2010) 1.30
Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum (2007) 1.30
Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis (2010) 1.29
Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis (2004) 1.29
Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol (1999) 1.29
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis (2008) 1.28
European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus (2009) 1.28
A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. Rheumatology (Oxford) (2002) 1.27
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis (2014) 1.27
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2009) 1.27
MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann Rheum Dis (2005) 1.27
Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis (2003) 1.26
What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis (2013) 1.25
Rheumatoid nodules: differential diagnosis and immunohistological findings. Ann Rheum Dis (1993) 1.23